A federal docket on the therapeutic use of psychedelics is open through October 5. Four groups that built this movement from the ground up on what they’d tell the government, what they’re fighting in court, and how much of their work the docket doesn’t cover.
The Food and Drug Administration held a public hearing on the potential therapeutic uses of psychedelic drugs on September 14. The part that is still open is the written comment period, which runs through October 5 under docket FDA-2026-N-7542, and anyone can file to it.
Britton “Britt” Rollins, co-founder of the Oregon-based National Psychedelics Association, wants people to use it. “We’re asking that anyone who has experienced psilocybin or seen the benefits of psilocybin-assisted therapy should make their voices heard during this open-comment period,” he says.
Worth knowing before you write: the notice is narrower than the invitation. The FDA framed the proceeding around the therapeutic use of a range of psychedelic compounds, not psilocybin specifically, and said it is not seeking comment on legalization, decriminalization, the merits of state or local programs, or religious, ceremonial or personal non-medical use. A comment that simply argues mushrooms improved someone’s marriage falls outside what the agency says it is seeking. A comment about clinical evidence, trial design, safety monitoring, practitioner training and credentialing, or barriers to therapeutic access does not.
Britton “Britt” Rollins, co-founder of the National Psychedelics Association. Photo courtesy of the National Psychedelics Association.
The hearing did not come out of nowhere. On April 18, 2026, President Trump signed Executive Order 14401, “Accelerating Medical Treatments for Serious Mental Illness.” It directs the FDA to give priority-review vouchers to qualifying psychedelic drugs that already hold Breakthrough Therapy designation, directs the FDA and DEA to establish a Right to Try pathway for eligible patients, and orders HHS, …
Read More
Author: Mark Miller / High Times
